van den Bent MJ, Tesileanu CMS, Wick W et al (2021) Adjuvant and concurrent Temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053– 22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813–823. https://doi.org/10.1016/s1470-2045(21)00090-5

Article  PubMed  PubMed Central  CAS  Google Scholar 

Neuroendocrine and Adrenal Tumors (2025) NCCN Clinical Practice Guidelines in Oncology

Hart MG, Garside R, Rogers G et al (2013) Temozolomide for high grade glioma. Cochrane Database Syst Rev https://doi.org/10.1002/14651858.CD007415.pub2

Article  PubMed  PubMed Central  Google Scholar 

Cui X, Wang Y, Zhou J et al (2023) Expert opinion on translational research for advanced glioblastoma treatment. Cancer Biology Med 20:344–352. https://doi.org/10.20892/j.issn.2095-3941.2023.0012

Article  CAS  Google Scholar 

Stupp R, Mason WP, Bent MJvd et al (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

Article  PubMed  CAS  Google Scholar 

Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol; 27:4733–4740. https://doi.org/10.1200/jco.2008.19.8721

Article  PubMed  CAS  Google Scholar 

McFarlane T, Rehman N, Wang K et al (2019) Cutaneous toxicities of new targeted cancer therapies: must know for diagnosis, management, and patient-proxy empowerment. Annals Palliat Med 9:1296–1306

Article  Google Scholar 

Wick W, Puduvalli VK, Chamberlain MC et al (2010) Phase III study of Enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol 28:1168–117420100201. https://doi.org/10.1200/jco.2009.23.2595

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lombardi G, De Salvo GL, Brandes AA et al (2019) Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol 20:110–119. https://doi.org/10.1016/s1470-2045(18)30675-2

Article  PubMed  CAS  Google Scholar 

Villano JL, Seery TE, Bressler LR (2009) Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64:647–655. https://doi.org/10.1007/s00280-009-1050-5

Article  PubMed  CAS  Google Scholar 

Chastain DB, Hutzley VJ, Parekh J et al (2019) Antimicrobial desensitization: A review of published protocols. Pharm (Basel) https://doi.org/10.3390/pharmacy7030112

Article  Google Scholar 

Virmani P, Chung E, Thomas AA et al (2015) Cutaneous adverse drug reaction associated with oral Temozolomide presenting as dermal and subcutaneous plaques and nodules. JAAD Case Rep 1:286–288. https://doi.org/10.1016/j.jdcr.2015.06.012

Article  PubMed  PubMed Central  Google Scholar 

Farshchian M, Bardhi R, Daveluy S (2021) Desquamative skin rash associated with Temozolomide in a patient with glioblastoma. Dermatol Ther 34:e14771. https://doi.org/10.1111/dth.14771

Article  PubMed  Google Scholar 

Mehta H, Gendle CS, Kumaran MS et al (2023) Temozolomide-induced drug rash with eosinophilia and systemic symptoms syndrome. Indian J Dermatol Venereol Leprol 89:160. https://doi.org/10.25259/ijdvl_754_2021

Article  PubMed  Google Scholar 

Sarma N (2009) Stevens-Johnson syndrome and toxic epidermal necrolysis overlap due to oral Temozolomide and cranial radiotherapy. Am J Clin Dermatol 10:264–267. https://doi.org/10.2165/00128071-200910040-00007

Article  PubMed  Google Scholar 

Deluche E, Leobon S, Touraine F et al (2014) Two cases of cutaneous drug eruption associated with Temozolomide therapy for glioblastoma. Curr Oncol 21:e779–781. https://doi.org/10.3747/co.21.2133

Article  PubMed  PubMed Central  CAS  Google Scholar 

Mhanna H, Jiménez Blanco A, Valdez Tejeda M et al (2011) Desensitization to Temozolomide. J Allergy Clin Immunol 127:AB197. https://doi.org/10.1016/j.jaci.2010.12.783

Article  Google Scholar 

Mónica RG, De Las Heras Gozalo M, De La Barrera HG, Sastre Dominguez E (2011) Successful desensitization with Temozolomide. Annals Allergy Asthma Immunol. https://doi.org/10.1016/j.anai.2011.02.009

Article  Google Scholar 

Clayton E, Madamba J, Kong XT, Braskett M (2014) Successful desensitization protocol for delayed cutaneous eruption to Temozolomide. J Allergy Clin Immunol Pract 2(5):626–628. https://doi.org/10.1016/j.jaip.2014.03.016

Article  PubMed  Google Scholar 

Sun S, Lee D, Lee NP et al (2012) Hyperoxia resensitizes chemoresistant human glioblastoma cells to Temozolomide. J Neurooncol 109:467–47520120705. https://doi.org/10.1007/s11060-012-0923-3

Article  PubMed  PubMed Central  CAS  Google Scholar 

Neth BJ, Ruff MW, Uhm JH et al (2020) Temozolomide desensitization followed by metronomic dosing in patients with hypersensitivity. Cancer Chemother Pharmacol 86(20200810):375–382. https://doi.org/10.1007/s00280-020-04123-y

Article  PubMed  CAS  Google Scholar 

Sferruzza G, Malcangi M, Bosco L et al (2024) Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: A systematic review and external pseudodata-based analysis. Neuro-Oncology Adv https://doi.org/10.1093/noajnl/vdad174

Article  Google Scholar